BR112016030326A2 - ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv? - Google Patents

?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv?

Info

Publication number
BR112016030326A2
BR112016030326A2 BR112016030326A BR112016030326A BR112016030326A2 BR 112016030326 A2 BR112016030326 A2 BR 112016030326A2 BR 112016030326 A BR112016030326 A BR 112016030326A BR 112016030326 A BR112016030326 A BR 112016030326A BR 112016030326 A2 BR112016030326 A2 BR 112016030326A2
Authority
BR
Brazil
Prior art keywords
particles
vectors
immunogenic composition
polynucleotide
preventing
Prior art date
Application number
BR112016030326A
Other languages
English (en)
Other versions
BR112016030326B1 (pt
Inventor
Shakuntabai Anavaj
Roth Claude
Simon-Loriere Etienne
Tangy Frédéric
Buchy Philippe
Original Assignee
Centre Nat Rech Scient
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Pasteur Institut filed Critical Centre Nat Rech Scient
Publication of BR112016030326A2 publication Critical patent/BR112016030326A2/pt
Publication of BR112016030326B1 publication Critical patent/BR112016030326B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção refere-se a um poliepítopo quimérico do vírus da dengue composto de fragmentos de proteínas não estruturais e seu uso em uma composição imunogênica contra infecção pelo vírus da dengue. a presente invenção fornece meios, particularmente polinucleotídeos, vetores, células e métodos de produção de vetores que expressam os mencionados poliepítopos quiméricos, particularmente vetores que consistem de partículas de vírus do sarampo (mv) recombinantes. a presente invenção também se refere ao uso das partículas de mv recombinantes, particularmente sob a forma de composição ou vacina, para prevenção e/ou tratamento de infecções por vírus da dengue.
BR112016030326-1A 2014-06-23 2015-06-22 Poliepítopo quimérico, polinucleotídeo, vetor, vetores de genoma de vírus do sarampo (mv) recombinantes, partículas de mv recombinantes,composições imunogênicas, uso das partículas de mv recombinantes e método de produção de partículas de mv recombinantes BR112016030326B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305984.8 2014-06-23
EP14305984.8A EP2959915A1 (en) 2014-06-23 2014-06-23 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
PCT/EP2015/064010 WO2015197565A1 (en) 2014-06-23 2015-06-22 A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

Publications (2)

Publication Number Publication Date
BR112016030326A2 true BR112016030326A2 (pt) 2017-10-24
BR112016030326B1 BR112016030326B1 (pt) 2023-10-31

Family

ID=51062758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030326-1A BR112016030326B1 (pt) 2014-06-23 2015-06-22 Poliepítopo quimérico, polinucleotídeo, vetor, vetores de genoma de vírus do sarampo (mv) recombinantes, partículas de mv recombinantes,composições imunogênicas, uso das partículas de mv recombinantes e método de produção de partículas de mv recombinantes

Country Status (12)

Country Link
US (2) US10316066B2 (pt)
EP (2) EP2959915A1 (pt)
JP (1) JP6486973B2 (pt)
KR (1) KR102557390B1 (pt)
CN (1) CN107074913B (pt)
AU (1) AU2015279375B2 (pt)
BR (1) BR112016030326B1 (pt)
CA (1) CA2952531C (pt)
MX (1) MX2017000169A (pt)
PH (1) PH12016502554B1 (pt)
SG (1) SG11201610731VA (pt)
WO (1) WO2015197565A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331559A4 (en) * 2015-08-03 2019-03-06 The United States of America as represented by the Secretary of the Army, Walter Reed Army Institute Of Research (WRAIR) PROTEIN OF RECOMBINANT DENGUE ENHANCING IMMUNITY
CN105801674B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p7及其应用
CN105777877B (zh) * 2016-04-05 2019-03-12 首都医科大学 登革病毒e蛋白阻断肽p4及其应用
WO2017221076A1 (en) 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
SG11202004234SA (en) * 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
WO2020014658A1 (en) * 2018-07-13 2020-01-16 University Of Georgia Research Foundation Broadly reactive immunogens of dengue virus, compositions, and methods of use thereof
EP4208193A1 (en) * 2020-09-01 2023-07-12 Helmholtz-Zentrum für Infektionsforschung GmbH Multi-patch vaccines and immunogenic compositions, methods of production and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE231557T1 (de) * 1991-11-21 2003-02-15 Common Services Agency Detektion des hepatis-c virus.
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
ZA200900483B (en) * 2006-07-14 2010-03-31 Sanofi Pasteur Biologics Co Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
WO2011110953A2 (en) * 2010-03-09 2011-09-15 Artemev, Timur Polyepitope constructs and methods for their preparation and use
WO2011163628A2 (en) * 2010-06-24 2011-12-29 La Jolla Institute For Allergy And Immunology Dengue virus (dv) polypeptide sequences, t cell epitopes and methods and uses thereof
WO2012178196A2 (en) * 2011-06-24 2012-12-27 La Jolla Institute For Allergy And Immunology Protection against dengue virus and prevention of severe dengue disease

Also Published As

Publication number Publication date
US20190300578A1 (en) 2019-10-03
JP2017520252A (ja) 2017-07-27
PH12016502554A1 (en) 2017-04-10
BR112016030326B1 (pt) 2023-10-31
EP2959915A1 (en) 2015-12-30
US11034730B2 (en) 2021-06-15
CN107074913A (zh) 2017-08-18
JP6486973B2 (ja) 2019-03-20
EP3157555A1 (en) 2017-04-26
US20170158740A1 (en) 2017-06-08
KR20170020513A (ko) 2017-02-22
CN107074913B (zh) 2022-02-25
WO2015197565A1 (en) 2015-12-30
AU2015279375A1 (en) 2017-01-05
MX2017000169A (es) 2017-06-29
PH12016502554B1 (en) 2017-04-10
CA2952531A1 (en) 2015-12-30
KR102557390B1 (ko) 2023-07-19
US10316066B2 (en) 2019-06-11
CA2952531C (en) 2021-12-28
SG11201610731VA (en) 2017-01-27
AU2015279375B2 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
BR112016030326A2 (pt) ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv?
MX2018014573A (es) Vacuna contra el virus del zika.
WO2018115507A3 (en) Henipavirus vaccine
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
BR112018012873A2 (pt) vacina de vírus zika
WO2016070166A3 (en) Messenger una molecules and uses thereof
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112016027897A2 (pt) polipeptídio multimérico, ácido nucleico, vetor de expressão recombinante, célula hospedeira geneticamente modificada, composição, método, e, método de tratamento de uma infecção num indivíduo
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
MX2016004063A (es) Variante de la proteina pcv2 orf2 y particulas similares al virus compuestas por esta.
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
NZ723328A (en) Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
BR112016023304A2 (pt) célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
BR112017004770A2 (pt) partícula tipo flavivírus
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2015, OBSERVADAS AS CONDICOES LEGAIS